Intellia Therapeutics Stock Surges on Gene-Editing Trial Success
Published on 11/18/2025 at 12:47 | Redaktion boerse-global.de
Intellia Therapeutics captured significant market attention on November 16 when the biotechnology firm unveiled groundbreaking clinical trial data for its CRISPR-based therapy, nexiguran ziclumeran (nex-z). The phase 1 study results focused on treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM), with findings simultaneously published in the prestigious New England Journal of Medicine—a strong indicator of the data’s scientific importance.
The company’s shares demonstrated considerable volatility around the announcement, trading between $13.12 and $15.20 during the presentation period. This marks the first demonstration that Intellia’s gene-editing approach can positively impact the progression of this rare but fatal condition.
In the phase 1 trial involving 36 ATTR-CM patients, half were classified as New York Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
